Table 3. Grade 3 or 4 Adverse Events among Patients with Negative PET Findings Who Started Their Assigned Treatment.^*.

Event	ABVD, Cycles 1 and 2 (N =1203)	ABVD, Cycles 3–6 (N = 468)	AVD, Cycles 3–6 (N = 457)	BEACOPP-14 (N = 94)	Escalated BEACOPP (N = 78)
			number (percent)
Any blood or bone marrow event	711 (59)	280 (60)	273 (60)	68 (72)	58 (74)
Neutropenia	694 (58)	275 (59)	269 (59)	59 (63)	52 (67)
Thrombocytopenia†	16 (1)	6 (1)	15 (3)	18 (19)	33 (42)
Any cardiac event	9 (1)	6 (1)	2 (<0.5)	1 (1)	0
Any constitutional symptom	36 (3)	18 (4)	13 (3)	11 (12)	11 (14)
Fatigue†	14 (1)	14 (3)	5 (1)	8 (9)	3 (4)
Fever	16 (1)	4 (1)	7 (2)	2 (2)	9 (12)
Any infection	76 (6)	68 (15)	47 (10)	35 (37)	33 (42)
Febrile neutropenia†	24 (2)	22 (5)	10 (2)	10 (11)	20 (26)
Any neurologic event	20 (2)	23 (5)	14 (3)	9 (10)	3 (4)
Any pulmonary or upper respiratory event†	8 (1)	15 (3)	3 (1)	4 (4)	4 (5)
Dyspnea†	5 (<0.5)	9 (2)	1 (<0.5)	2 (2)	2 (3)
Pneumonitis	0	5 (1)	1 (<0.5)	0	2 (3)
Any vascular event	18 (1)	23 (5)	12 (3)	8 (9)	2 (3)
Thrombosis or embolism related to vascular access	4 (<0.5)	4 (1)	1 (<0.5)	0	0
Thrombosis, thrombus, or embolism	14 (1)	20 (4)	11 (2)	8 (9)	2 (3)
Any clinical adverse event‡§	188 (16)	143 (31)	96 (21)	52 (55)	47 (60)
Any grade 3 or 4 adverse event	771 (64)	322 (69)	299 (65)	75 (80)	65 (83)

^*Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. BEACOPP-14 is an accelerated version of BEACOPP that involves growth-factor support. Escalated BEACOPP involves higher-than-standard doses of etoposide, doxorubicin, and cyclophosphamide.

^†P<0.05 for the comparison of ABVD with AVD during cycles 3 through 6.

^‡Blood or bone marrow events and laboratory events were excluded.

^§P<0.005 for the comparison of ABVD with AVD during cycles 3 through 6.